文献速递胸部肿瘤

靶向RET治疗RET重排肺癌患者:全球多中心RET登记研究结果

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.
PubMed 文献 · J Clin Oncol · 2017-03-13

该全球多中心登记研究纳入165例RET重排非小细胞肺癌患者,其中53例序贯接受至少一种RET酪氨酸激酶抑制剂治疗。卡博替尼、凡德他尼和舒尼替尼的客观缓解率分别为37%、18%和22%,中位无进展生存期2.3个月,中位总生存期6.8个月。作者认为现有多种激酶抑制剂在这类患者中活性有限。

要点

  • RET重排NSCLC以KIF5B-RET最常见(72%),多数为从不吸烟者(63%)和腺癌(98%)。
  • 卡博替尼、凡德他尼、舒尼替尼的完全或部分缓解率分别为37%、18%、22%。
  • 中位无进展生存期2.3个月,中位总生存期6.8个月。

核心结论

  • 在这项回顾性研究中,现有多种激酶抑制剂对RET重排NSCLC患者的活性有限,需要进一步研究其生物学并寻找新的靶向治疗以改善预后。

研究设计与样本

  • 全球多中心胸科肿瘤学家网络识别经病理确诊且携带RET重排的NSCLC患者,分子检测在当地通过逆转录聚合酶链反应、荧光原位杂交或二代测序完成,匿名临床、病理和分子数据集中收集并由独立统计师分析。
  • 截至2016年4月,共纳入来自欧洲、亚洲和美国29个中心的165例RET重排NSCLC患者,中位年龄61岁(范围29至89岁)。

主要发现

  • 多数患者为从不吸烟者(63%)、肺腺癌(98%)和晚期疾病(91%),最常见重排为KIF5B-RET(72%)。
  • 53例患者序贯接受至少一种RET酪氨酸激酶抑制剂:卡博替尼21例、凡德他尼11例、舒尼替尼10例、索拉非尼2例、阿来替尼2例、仑伐替尼2例、尼达尼布2例、帕纳替尼2例、瑞戈非尼1例。
  • 卡博替尼、凡德他尼和舒尼替尼的完全或部分缓解率分别为37%、18%和22%,仑伐替尼和尼达尼布也观察到进一步缓解。
  • 中位无进展生存期为2.3个月(95%CI,1.6至5.0个月),中位总生存期为6.8个月(95%CI,3.9至14.3个月)。

局限性

  • 原文指出这是一项回顾性研究。
  • 原文结论提出需要进一步研究RET重排肺癌的生物学并识别新的靶向治疗以改善这些患者的预后。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose In addition to prospective trials for non-small-cell lung cancers (NSCLCs) that are driven by less common genomic alterations, registries provide complementary information on patient response to targeted therapies. Here, we present the results of an international registry of patients with RET-rearranged NSCLCs, providing the largest data set, to our knowledge, on outcomes of RET-directed therapy thus far. Methods A global, multicenter network of thoracic oncologists identified patients with pathologically confirmed NSCLC that harbored a RET rearrangement. Molecular profiling was performed locally by reverse transcriptase polymerase chain reaction, fluorescence in situ hybridization, or next-generation sequencing. Anonymized data-clinical, pathologic, and molecular features-were collected centrally and analyzed by an independent statistician. Best response to RET tyrosine kinase inhibition administered outside of a clinical trial was determined by RECIST v1.1. Results By April 2016, 165 patients with RET-rearranged NSCLC from 29 centers across Europe, Asia, and the United States were accrued. Median age was 61 years (range, 29 to 89 years). The majority of patients were never smokers (63%) with lung adenocarcinomas (98%) and advanced disease (91%). The most frequent rearrangement was KIF5B-RET (72%). Of those patients, 53 received one or more RET tyrosine kinase inhibitors in sequence: cabozantinib (21 patients), vandetanib (11 patients), sunitinib (10 patients), sorafenib (two patients), alectinib (two patients), lenvatinib (two patients), nintedanib (two patients), ponatinib (two patients), and regorafenib (one patient). The rate of any complete or partial response to cabozantinib, vandetanib, and sunitinib was 37%, 18%, and 22%, respectively. Further responses were observed with lenvantinib and nintedanib. Median progression-free survival was 2.3 months (95% CI, 1.6 to 5.0 months), and median overall survival was 6.8 months (95% CI, 3.9 to 14.3 months). Conclusion Available multikinase inhibitors had limited activity in patients with RET-rearranged NSCLC in this retrospective study. Further investigation of the biology of RET-rearranged lung cancers and identification of new targeted therapeutics will be required to improve outcomes for these patients.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Gautschi O, Milia J, Filleron T, et al. Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. J Clin Oncol. 2017. PMID: 28447912. doi:10.1200/JCO.2016.70.9352

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。